Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


EC bill

This article was originally published in The Tan Sheet

Executive Summary

Representative Steven Rothman, D-N.J., et al. introduced H.R. 464, the Compassionate Assistance for Rape Emergencies Act of 2007, on Jan. 12 to require hospitals that receive federal funds through Medicare or Medicaid to provide information on emergency contraceptives and offer such products to female patients being treated following sexual assaults. The bill was referred to the Energy and Commerce and Ways and Means committees...

You may also be interested in...

EC for rape survivors

The Connecticut Senate passes a bill April 25 to require licensed health care facilities to provide sexual assault survivors with emergency contraception upon request. The bill (S.B. 1343) moves to the House for a vote. Separately, the Wisconsin Legislature addresses a similar measure (S.B. 129) in a public hearing April 25. The Wisconsin bill not only provides emergency contraception upon request, but penalizes noncompliant hospitals. Also, Rep. Michael Michaud, D-Maine, et al., introduce a bill (H.R. 2064) April 26 to require the availability of emergency contraceptives to all military health care treatment facilities. The bill is referred to the House Committee on Armed forces. In January, Rep. Steven Rothman, D-N.J., et al., introduced legislation (H.R. 464) requiring hospitals receiving federal funds to provide information on EC as well as the product for women treated for sexual assault at the facility (1"The Tan Sheet" Jan. 29, 2007, In Brief)...

GeNeuro To Tackle Long COVID By Targeting Ancestor Viral Gene Activation

Switzerland’s GeNeuro will study whether its monoclonal antibody temelimab can prevent long-COVID, after data for the first time linked activation of human endogenous retroviruses (HERVs) to the condition and its associated neurological symptoms.

Executives On The Move: CFO Promoted At Novavax, Gilead Gets New Executive Vice President Of Research

Alpha Cognition, F2G and Immune Pharmaceuticals pick up new CEOs, and there is a new chief medical officer at Gemini Therapeutics.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts